On Friday, the U.S. Food and Drug Administration cleared Medtronic plc’s (NYSE:MDT) Stealth AXiS surgical system for spine surgery.
The Stealth AXiS system is cleared for spine procedures in the United States, with an underlying architecture designed to support future cranial and ENT applications, pending 510(k) clearance.
Built to support a wide range of surgeon preferences, clinical complexity, and care settings, the platform is designed for use across hospitals and ambulatory surgery centers without relying on multiple standalone technologies.
Spine Surgery System
The Stealth AXiS system is built to support a variety of surgical preferences and complexities, allowing for real-time visibility into anatomical motion during procedures.
A key innovation of the Stealth AXiS system is LiveAlign segmental tracking, a capability that allows surgeons to visualize anatomic motion, surgical adjustments, and patient alignment in real time during spine surgery, without the need for repeated imaging.
This capability helps reduce reliance on manual steps and workflow disruption, supporting more consistent execution of patient-specific surgical plans.
Technical Analysis
Currently, Medtronic is trading 0.28% below its 20-day simple moving average (SMA) and 1.18% above its 100-day SMA, suggesting a mixed short-term trend. Over the past 12 months, shares have increased 9.41% and are positioned closer to their 52-week highs than lows, reflecting a generally positive longer-term trend.
The RSI is at 49.61, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum for Medtronic’s stock.
- Key Resistance: $101.50
- Key Support: $99.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price forecast of $110.29. Recent analyst moves include:
- Needham: Upgraded to Buy (Target $121)
- Bernstein: Outperform (Raises Target to $112)
- Barclays: Overweight (Raises Target to $116)
Valuation Insight: While the stock trades at a premium P/E multiple, the strong consensus and rising estimates suggest analysts view the growth prospects as justification for the 9% upside to analyst targets.
Benzinga Edge Rankings
- Value: Weak (Score: 23.98) — Trading at a steep premium relative to peers.
- Quality: Strong (Score: 71.66) — Balance sheet remains healthy.
- Momentum: Neutral (Score: 58.65) — Stock is performing in line with the broader market.
The Verdict: Medtronic plc’s Benzinga Edge signal reveals a mixed outlook. While the Value score indicates potential overvaluation, the Quality score suggests a solid financial foundation, making it a stock to watch closely.
MDT Price Action: Medtronic shares were up 0.19% at $101.07 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments